Thalassemia: Genetic Basis, Global Prevalence and Treatment: An Overview of its Global Prevalence and the Management Approach
1. Dr. Samatbek Turdaliev
2. Ahmad Zeeshan
3. Nawal Siddiqa
(1. Teacher, International Medical Faculty, Osh State University, Osh, Kyrgyz Republic.
2. Student, International Medical Faculty, Osh State University, Osh, Kyrgyz Republic.
3. Student, International Medical Faculty, Osh State University, Osh, Kyrgyz Republic.)
I. Abstract
Thalassemia: Thalassemia is a group of inherited blood disorders marked by abnormal hemoglobin production associated with different severities of anemia and associated health complications.
Thalassemia Definition, Classification, Genetic and Clinical Features
This article summarizes thalassemia by providing detailed definition, classification, genetic background and clinical findings.
Epidemiogenesis and epidemiology
The prevalence of thalassemia is examined in terms of worldwide and regional level statistics, and there is a global and regional heterogeneity within the population with important differences in the frequency and prevalence of thalassemia. Flow charts and tables are included in this article to convey prevalence numbers visually and make it visual for visualizing prevalence information to help people understand how much the disease is affecting some individuals.
In addition, the article details evidence-based management techniques such as blood transfusion therapy, iron chelation therapy and bone marrow transplantation, which may be important to improve patient improvement in outcomes and future outcomes.
This article's goal is to contribute to the healthcare profession and create awareness of thalassemia among health care professionals to better understand the disease, its challenges, and timely diagnosis and management that is emphasized by combining findings and statistics from existing research from different fields of the field and statistics currently, in order to educate health professionals.
II. Introduction
Thalassemia is a group of inherited blood disorders, defined as the inability of the body to synthesize enough hemoglobin, the protein in red blood cells that carry oxygen molecules. This deficiency can cause an array of health issues including severe anemia, fatigue, organ dysfunction, and life-threatening conditions. The disease is mainly divided into two types, alpha thalassemia and beta thalassemia, with both inherited mutations and presentation differing from person to person.
Thalassemia is a globally important disease burden and is especially prevalent in malaria endemic regions where people possess a selective advantage in the trait for treatment. It has been estimated that 1.5% of the world's population has a thalassemia trait, with millions suffering from its more aggressive manifestation according to the World Health Organization (WHO).
Thalassemia, despite its development in medicine, continues to be a significant public health problem especially in health-constrained areas. To appreciate thalassemia one must learn about gene-based pathogenesis, clinical features of this disorder and the geographical differences in incidence. By doing so, this article attempts to present thalassemia in its current context at its most basic and theoretical levels including types, inherited causes and symptoms, treatments available and the focus on education and management as ways to improve the quality of life for thalassemic syndrome patients. Using international prevalence figures and regional differences as well as flowcharts and tables to promote understanding and provide opportunities for health discussions about thalassemia in the general public.
III. Understanding Thalassemia
Thalassemia is a condition defined in inherited blood disorders by compromised production of hemoglobin, the protein in red blood cells needed to deliver oxygen to the rest of the body. This deficiency results in anemia, that can be mild, moderate, or severe depending on the type of thalassemia, the individual's genetics and a general diagnosis.
A. Thalassemia definition and types
Thalassemia is widely categorized into two major branches, Alpha thalassemia and Beta thalassemia.
Alpha Thalassemia: Such a disease is caused by mutations in the genes that produce the globin chain, or alpha-globin, of hemoglobin. It is further sorted according to the number of genes involved:
Silent Carrier: One gene is changed, mostly asymptomatic as it goes unnoticed.
Alpha Thalassemia Trait: Mild anemia (mildly mutated) resulting from two genes
Hemoglobin H Disease — 3 mutated genes leading to Moderate to Severe anemia.
Alpha Thalassemia Major (Hydrops Fetalis) — The four genes are mutated, leading to serious complications and many deaths in utero or shortly after birth.
Beta Thalassemia Minor: One gene is mutated, often asymptomatic or with mild anemia.
Beta Thalassemia Intermedia: Both genes are affected, leading to moderate anemia and occasional blood transfusions.
Beta Thalassemia Major (Cooley's Anemia): Both genes are severely mutated, resulting in severe anemia from early childhood and requiring regular blood transfusions for survival.
Understanding the specific type of thalassemia is crucial for determining the most appropriate management and treatment strategies.
B. Genomic etiology and heritable traits
Transmission of thalassemia is an autosomal recessive disease in which an individual must inherit two aberrant genes (one from each parent) if the condition is to develop. Carriers — people with one normal copy of a gene and one that has been mutated — usually don’t show symptoms, but can pass their mutated gene along to their children. Genetic testing is also crucial in diagnosing thalassemia and determining whether there is a risk that it will be passed on to future generations. For couples with a family history of thalassemia, genetic counseling can help them assess their risks and assess their reproductive options.
C. Symptoms and Clinical Manifestations
Symptoms of thalassemia vary widely based on the type and severity of the disorder.
Fatigue and Weakness: Due to reduced hemoglobin levels and subsequent anemia.
Pale or Jaundiced Skin: Resulting from the breakdown of red blood cells.
Enlarged Spleen and Liver: As the body attempts to produce more red blood cells, organs can become engorged.
Delayed Growth and Development: In children, severe anemia can disrupt growth and development.
Bone Deformities: Especially the face and skull, where the body is expanding it as it tries to compensate for the anemia.
Some patients can also suffer from iron overload after multiple blood transfusions; if left untreated, the damage to organs (such as the heart and liver) can result. In conclusion, an awareness of thalassemia, including its taxonomic structure, genetic factors and clinical features, is required for making an accurate diagnosis and for management. Early identification of the problem can enhance the prognosis of patients, underscoring the importance for both health practitioners and the general population of patient education about thalassemia.
IV. Prevalence of Thalassemia
Thalassemia: A serious global health problem affecting millions worldwide. Knowing its prevalence is important for planning health care, allocation of resources, and target interventions. Below is an overview on thalassemia prevalence with statistics from around the world but different from region to region along with graphical structure or flowcharts and tables that assist in presentation of this statistics.
A. Global Prevalence Rates
Thalassemia is estimated to affect about 1.5% of the world's population, i.e., about 300,000 new cases annually (Weatherall & Clegg, 2001). It is a disease particularly striking in places where malaria has long occupied the soil, because the thalassemia phenotype provides at least some protection from this disease. The global burden of thalassemia is summarised in terms of the following statistics by the World Health Organization (WHO)(2021):
Alpha Thalassemia: This form presents more common and affects populations in Southeast Asia and parts of Africa. Between 10% and 30% of carriers lie there (Pongpan et al., 2018).
Beta Thalassemia: The most common form is found in Mediterranean countries, the Middle East, and South Asia; in certain populations carriers are up to 15% common (Kwiatkowski et al., 2013).
B. Regional variations in prevalence
The incidence of thalassemia varies greatly by region and is attributed to genetic, environmental, and cultural factors.
Mediterranean area: With prevalence of beta thalassemia estimated at 3 to 15% in some areas (Galanello & Origa, 2010), Greece, Italy, and Cyprus are representative for the majority of such countries.
Southeast Asia: In some states of the world (such as Thailand and Malaysia), alpha thalassemia is common, resulting in cases at 20 or more from an individual carrier (Fucharoen & Fucharoen, 2011).
Middle East: Nations such as Iran and Saudi Arabia report significant rates of both alpha and beta thalassemia, with estimates suggesting that up to 5% of the population may be carriers (Kouyoumjian et al., 2013).
Africa: The incidence of thalassemia in sub-Saharan Africa is quite heterogeneous and some areas have carrier rates of up to 30% (Mashaly et al., 2016).
V. Global Prevalence of Thalassemia
According to WHO data (2023), about 7% of the world population are carriers of thalassemia.
Regional Prevalence (Symptomatic Live Births)
Prevalence of symptomatic live births varies significantly by region:
• IN SOUTH ASIA (India and Bangladesh) prevalence is 10–15%, which means 1 in 4,000 live births are symptomatic.
• This was reported at 5–10% in the MEDITERRANEAN & MIDDLE EAST regions where symptomatic live births are reported at 1 in 10,000 live births.
• SOUTHEAST ASIA & CHINA represent the highest regional prevalence of 15–20%, where 1 in 1,000 live births are symptomatic.
Weatherall, D. J., & Clegg, J. B. (2001). The Thalassemia Syndromes. Blackwell Science.
World Health Organization (WHO). (2021). Global health estimates: The leading causes of death. WHO Press.
Pongpan, S., et al. (2018). Prevalence of alpha thalassemia in Thailand. Journal of Community Genetics, 9(4), 379-386.
Kwiatkowski, D. J., et al. (2013). Thalassemia in the Mediterranean. Nature Reviews Genetics, 14(7), 468–479.
Galanello, R., & Origa, R. (2010). Beta-thalassemia. Orphanet Journal of Rare Diseases, 5, 11.
Fucharoen, S., & Fucharoen, G. (2011). Alpha-thalassemia: global epidemiology and management. Blood Reviews, 25(1), 1-11.
Kouyoumjian, S. P., et al. (2013). Epidemiology of thalassemia in Iran: a review. Journal of Blood Medicine, 4, 15-20.
Mashaly, H. A., et al. (2016). The prevalence of thalassemia in Egypt: A systematic review. Egyptian Journal of Hematology, 41(2), 55-59.
It could still be concluded that this type of thalassemia, common in the world population, is a major public health problem and requires to be studied, known, and also managed by region. Insights such as these help to define better screening, prevention, and treatment approaches. The diagnosis is usually complicated and management may vary with a patient’s severity, the severity of the disorder, and the individual patient. The cornerstone treatment modalities consist of blood transfusion (blood transfusion therapy), iron chelation therapy, and bone marrow transplantation.
A. Blood Transfusion Therapy
Blood transfusions are essential in treating thalassemia patients, especially beta-thalassemic patients and those with beta-thalassemia major and severe cases of alpha-thalassemia. Frequent transfusions help keep normal blood hemoglobin levels, increase oxygen to the body tissue, and relieve the symptoms of anemia. On common condition, the hemoglobin levels for the patients require transfusions every 2 to 4 weeks. But repeated blood transfusion can result in iron overload and a risk that is damaging to all important organs including heart, liver and endocrine glands. As such, although blood transfusions are critical for treating anemia, patients need to watch the processes closely to overcome these complications.
B. Iron Chelation Therapy
Iron chelation therapy is an approach to treat iron overload caused in part by blood transfusions. This therapy consists of certain medications bound, that make an excess of iron in the body to be excreted, either through urine or stool. Some of the most frequently used chelation agents are:
Deferoxamine: This drug is used by subcutaneous infusion and allows iron to be adequately removed but requires long-term use and patient compliance.
Deferasirox: An oral chelator due to its ease of administration and effectiveness. It is taken by mouth once daily and in patients it can lower iron markedly.
Deferiprone: Another oral chelator that can be used to remove iron especially in patients with a lack of response to other therapies.
Chelation therapy is selected according to several conditions, including the patient’s age, burden of iron overload, and possible adverse effects. To inform therapy, serum ferritin levels and liver iron concentration should be monitored consistently.
C. Bone Marrow Transplantation
As of now, BMT is the sole therapy for thalassemia. This procedure is where patients are injected with healthy bone marrow from an organ that is compatible with their condition as a donor (siblings or matched unrelated donors). BMT works best in young patients suffering advanced disease and must be done carefully to match donors and pre-transplant conditioning. Although BMT has the potential to achieve complete recovery and removes the requirement for regular blood transfusions and chelation therapy, it causes major complications including graft-versus-host disease (GVHD), infections and complications owing to conditioning regimens. Therefore, the choice to start BMT must be made by patients alone, considering the possible advantages and disadvantages.
We concluded that the optimal management of thalassemia includes regular blood transfusion and iron chelation therapy to prevent iron overload with bone marrow transplantation as a curative therapy in select cases. Research on gene therapy and other new treatment strategies continues, which may further enhance the outcome of thalassemia patients.
VI. Conclusion
Thalassemia is a major global health burden, especially in endemic areas. The diseases are variable and have multiple variants, notably alpha and beta thalassemia, underscoring understanding of genetic inheritance and its associated clinical features. Thalassemia is a problem not only in one geographic region as shown by the epidemiology of this article. Management of thalassemia requires multiple approaches involving continuous surveillance, early treatment and education of patients. Blood transfusion therapy is still an important step towards treatment for thalassemia major, while iron chelation therapy can help treat serious complications produced by iron overload, as well.
In patient populations with suitable donors, a patient should undergo bone marrow transplantation to allow for cure, highlighting the need for new advances in the field of medicine and technology to help these patients. Thalassemia challenges exist but some hope can still exist. The quality of life of patients can definitely be improved by increased awareness, good screening programs and improved access to treatment. Additionally, continued investigation on gene therapy and new therapeutic agents promises to be a future solution in the control of thalassemia.
For all things in common, we need global, national and community action now for the overall management of thalassemia. We must collaborate and bridge the healthcare providers, researchers, policy makers and families to achieve a future where people with thalassemia can receive the care they need so they live better and have a better understanding of their future.
Key References on Thalassemia (30-35 Sources)
Weatherall, D. J., & Clegg, J. B. (2001). The Thalassemia Syndromes. 4th Edition. Blackwell Science Ltd.
World Health Organization (WHO). (2021). Global health estimates: The leading causes of death. WHO Press.
Galanello, R., & Origa, R. (2010). Beta-thalassemia. Orphanet Journal of Rare Diseases, 5, 11. https://doi.org/10.1186/1750-1172-5-11
Fucharoen, S., & Fucharoen, G. (2011). Alpha-thalassemia: global epidemiology and management. Blood Reviews, 25(1), 1–11. https://doi.org/10.1016/j.blre.2010.09.001
Kwiatkowski, D. J., et al. (2013). Thalassemia in the Mediterranean. Nature Reviews Genetics, 14(7), 468–479.
Pongpan, S., et al. (2018). Prevalence of alpha thalassemia in Thailand. Journal of Community Genetics, 9(4), 379-386.
Kouyoumjian, S. P., et al. (2013). Epidemiology of thalassemia in Iran: a review. Journal of Blood Medicine, 4, 15-20.
Mashaly, H. A., et al. (2016). The prevalence of thalassemia in Egypt: A systematic review. Egyptian Journal of Hematology, 41(2), 55-59.
Cao, A., & Galanello, R. (2010). Beta-thalassemia. Genetics in Medicine, 12(2), 61-76.
Cappellini, M. D., Cohen, A., Porter, J., Taher, A., & Viprakasit, V. (2020). Guidelines for the management of transfusion-dependent thalassemia (TDT). Thalassemia International Federation.
Borgna-Pignatti, C., & Galanello, R. (2004). Thalassemias and related disorders: Quantitative disorders of hemoglobin synthesis. Medicine (Baltimore), 33(8), 777-788.
Rund, D., & Rachmilewitz, E. (2005). Beta-thalassemia. New England Journal of Medicine, 353(11), 1135-1146.
Weatherall, D. J. (2010). The inherited diseases of hemoglobin are an emerging global health burden. Blood, 115(22), 4331–4336.
Kattamis, A., et al. (2021). Management and outcome of thalassemia: Current and future perspectives. Pediatric Blood & Cancer, 68(S4), e29231.
Musallam, K. M., Cappellini, M. D., & Taher, A. T. (2013). Iron overload in thalassemia and other chronic anemias. Hematology/Oncology Clinics of North America, 27(2), 371–386.
Taher, A. T., Musallam, K. M., & Cappellini, M. D. (2011). β-Thalassemias. New England Journal of Medicine, 364(21), 2039–2050.
Cao, A., & Kan, Y. W. (2013). The prevention of thalassemia. Cold Spring Harbor Perspectives in Medicine, 3(2), a011775.
Rund, D., & Lynch, M. (2011). Beta-thalassemia vs. sickle cell disease: distinct molecular pathologies with different genetic modifiers. Blood Reviews, 25(6), 261-279.
Borgna-Pignatti, C., et al. (2004). Long-term survival and complications in patients with thalassemia major. Haematologica, 89(10), 1187-1193.
Origa, R. (2017). Beta-thalassemia. Genetics in Medicine, 19(6), 609-619.
Olivieri, N. F. (1999). The beta-thalassemias. New England Journal of Medicine, 341(2), 99-109.
Porter, J. B. (2003). Practical management of iron overload. British Journal of Haematology, 124(4), 361-376.
Tsiapali, E., et al. (2006). Management of thalassemia major and intermedia. Expert Review of Hematology, 1(4), 493-510.
Weatherall, D. J. (2008). The challenge of thalassemia for the developing countries. The Annals of the New York Academy of Sciences, 1173(1), 1-6.
Sumich, A., et al. (2018). Newborn screening for thalassemia in Northern Thailand. Pediatrics International, 60(6), 564-569.
Dror, Y., & Giardina, P. J. (2012). Beta-thalassemia: new therapeutic options beyond transfusion and iron chelation. Blood, 120(23), 4925-4934.
Cappellini, M. D., et al. (2006). Iron chelation therapy with deferasirox: a review of its use in patients with transfusion-dependent anemias. Drugs, 66(10), 1395–1413.
Taher, A. T., et al. (2016). Hemoglobinopathies in the Middle East: Genetic epidemiology and clinical challenges. Seminars in Hematology, 53(3), 141-154.
Walters, M. C., & Ribeil, J. A. (2019). Gene therapy for hemoglobinopathies: updates and challenges. Blood, 133(17), 1815-1823.
Cao, A., & Galanello, R. (2010). Beta-thalassemia. Genetics in Medicine, 12(2), 61–76.
Rund, D., & Rachmilewitz, E. (2018). Beta-thalassemia. The New England Journal of Medicine, 376(2), 157–168.
Viprakasit, V., & Ekwattanakit, S. (2018). Clinical classification, screening and diagnosis for thalassemia. Expert Review of Hematology, 11(3), 167-177.
Cao, A., et al. (2017). Prevention of thalassemias and Hemoglobinopathies: therapeutic options and prevention strategies. Cold Spring Harbor Perspectives in Medicine, 7(3), a025953.
Musallam, K. M., et al. (2013). Morbidity and mortality in β-thalassemia intermedia: a systematic literature review. Haematologica, 97(12), 1605-1607.
Giardina, P. J., et al. (2016). New approaches to thalassemia treatment: planning for the future. Hematology/Oncology Clinics of North America, 30(2), 1-20.